EKDH.F Stock Overview
Engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
EKF Diagnostics Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.36 |
| 52 Week High | UK£0.40 |
| 52 Week Low | UK£0.36 |
| Beta | 0.57 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | -1.14% |
| Change since IPO | 18.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| EKDH.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -2.1% |
| 1Y | n/a | 22.4% | 29.6% |
Return vs Industry: Insufficient data to determine how EKDH.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how EKDH.F performed against the US Market.
Price Volatility
| EKDH.F volatility | |
|---|---|
| EKDH.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EKDH.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine EKDH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 309 | n/a | www.ekfdiagnostics.com |
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in Europe, the Middle East, the Americas, Asia, Africa, and internationally. It offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; Ultracrit, a hematocrit device; DiaSpect Hemoglobin T analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes; and STAT-Site M Beta-hydroxybutyrate analyzer.
EKF Diagnostics Holdings plc Fundamentals Summary
| EKDH.F fundamental statistics | |
|---|---|
| Market cap | US$181.09m |
| Earnings (TTM) | US$6.24m |
| Revenue (TTM) | US$66.57m |
29.0x
P/E Ratio2.7x
P/S RatioIs EKDH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EKDH.F income statement (TTM) | |
|---|---|
| Revenue | UK£50.95m |
| Cost of Revenue | UK£26.47m |
| Gross Profit | UK£24.48m |
| Other Expenses | UK£19.71m |
| Earnings | UK£4.78m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.011 |
| Gross Margin | 48.05% |
| Net Profit Margin | 9.37% |
| Debt/Equity Ratio | 0% |
How did EKDH.F perform over the long term?
See historical performance and comparison